REDWOOD CITY, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has commenced an underwritten public offering...

-- Continued robust treatment response from both high and low doses -- -- Long-term durability beyond 15 months from single IVT injection with zero rescue injections in Cohort 1 -- -- Well tolerated across all Cohorts; encouraging early safety data from Cohort 4 -- --...

REDWOOD CITY, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it will host a conference call and webcast on...

REDWOOD CITY, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Thomas Kochy joined the company as vice...

-- INFINITY trial is currently enrolling patients with DME, the most common cause of vision loss in people with diabetic retinopathy -- REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy...

-- Patients in Cohort 4 received ADVM-022 high dose 6x1011 vg and prophylactic steroid eye drops -- -- Data from all four cohorts planned by the end of 2020 -- REDWOOD CITY, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a...

-- Plans underway to begin expansion of manufacturing capabilities -- REDWOOD CITY, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...

-- Laurent Fischer, M.D. joins as CEO ---- Leone Patterson will continue to serve as president -- REDWOOD CITY, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs...

REDWOOD CITY, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the company will present at the Goldman Sachs...

-- INFINITY is a randomized, active comparator-controlled trial -- -- INFINITY trial initiated for patients with diabetic macular edema, the most common cause of vision loss in people with diabetic retinopathy -- -- Positive interim clinical data recently presented...